Invest Lithuania

Activities: Finance

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  2. CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
  3. ISPE announces 2024 Facility of the Year Awards category winners The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
  4. Tabletability, compactability and compressibility: What’s the difference? To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
  5. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Regulatory

Lithuania: a land of opportunity for clinical trials

In conversation with Karolina Karl, Head of the Life Sciences Team at Invest Lithuania, Dr Kevin Robinson discovers why the country offers such an attractive environment for sponsor companies and how accelerating clinical trials has emerged as a value proposition
Research & Development

Bringing biotech to the Baltics: the rise of Lithuania

Lithuania’s biotechnology competencies lie in cell and gene therapies, enzymes and the wider pharmaceutical industry, offering companies a rich pool of talent in a still-unsaturated market. Dr Kevin Robinson spoke with the country’s Minister for Economy and Innovation, Aušrinė Armonaitė, to find out more
Subscribe now